Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99


T2 Magnetic Resonance Assay-Based Direct Detection of Three Lyme Disease-Related Borrelia Species in Whole-Blood Samples.

Snyder JL, Giese H, Bandoski-Gralinski C, Townsend J, Jacobson BE, Shivers R, Schotthoefer AM, Fritsche TR, Green C, Callister SM, Branda JA, Lowery TJ.

J Clin Microbiol. 2017 Aug;55(8):2453-2461. doi: 10.1128/JCM.00510-17. Epub 2017 May 31.


Borrelia miyamotoi Infection in Patients from Upper Midwestern United States, 2014-2015.

Jobe DA, Lovrich SD, Oldenburg DG, Kowalski TJ, Callister SM.

Emerg Infect Dis. 2016 Aug;22(8):1471-3. doi: 10.3201/eid2208.151878.


Detection of IFN-γ Secretion by T Cells Collected Before and After Successful Treatment of Early Lyme Disease.

Callister SM, Jobe DA, Stuparic-Stancic A, Miyamasu M, Boyle J, Dattwyler RJ, Arnaboldi PM.

Clin Infect Dis. 2016 May 15;62(10):1235-1241. doi: 10.1093/cid/ciw112. Epub 2016 Mar 1.


The Emergence of Clinically Relevant Babesiosis in Southwestern Wisconsin.

Kowalski TJ, Jobe DA, Dolan EC, Kessler A, Lovrich SD, Callister SM.

WMJ. 2015 Aug;114(4):152-7.


Antibody responses to Borrelia burgdorferi outer surface proteins C and F in experimentally infected Beagle dogs.

Callister SM, LaFleur RL, Jobe DA, Lovrich SD, Wasmoen TL.

J Vet Diagn Invest. 2015 Jul;27(4):526-30. doi: 10.1177/1040638715583868. Epub 2015 Jun 11.


Vaccination with the ospA- and ospB-Negative Borrelia burgdorferi Strain 50772 Provides Significant Protection against Canine Lyme Disease.

LaFleur RL, Callister SM, Dant JC, Wasmoen TL, Jobe DA, Lovrich SD.

Clin Vaccine Immunol. 2015 Jul;22(7):836-9. doi: 10.1128/CVI.00193-15. Epub 2015 May 13.


Epidemiologic factors and urogenital infections associated with preterm birth in a midwestern U.S. population.

Agger WA, Siddiqui D, Lovrich SD, Callister SM, Borgert AJ, Merkitch KW, Mason TC, Baumgardner DJ, Burmester JK, Shukla SK, Welter JD, Stewart KS, Washburn MJ, Bailey HH.

Obstet Gynecol. 2014 Nov;124(5):969-77. doi: 10.1097/AOG.0000000000000470.


ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).

Go RS, Lee SJ, Shin D, Callister SM, Jobe DA, Conry RM, Tarhini AA, Kirkwood JM.

Clin Cancer Res. 2013 Dec 1;19(23):6597-604. doi: 10.1158/1078-0432.CCR-13-1414. Epub 2013 Oct 11.


Outer surface protein C peptide derived from Borrelia burgdorferi sensu stricto as a target for serodiagnosis of early lyme disease.

Arnaboldi PM, Seedarnee R, Sambir M, Callister SM, Imparato JA, Dattwyler RJ.

Clin Vaccine Immunol. 2013 Apr;20(4):474-81. doi: 10.1128/CVI.00608-12. Epub 2013 Jan 30.


Comparative whole-genome mapping to determine Staphylococcus aureus genome size, virulence motifs, and clonality.

Shukla SK, Pantrangi M, Stahl B, Briska AM, Stemper ME, Wagner TK, Zentz EB, Callister SM, Lovrich SD, Henkhaus JK, Dykes CW.

J Clin Microbiol. 2012 Nov;50(11):3526-33. doi: 10.1128/JCM.01168-12. Epub 2012 Aug 22.


Hamster and murine models of severe destructive Lyme arthritis.

Munson E, Nardelli DT, Du Chateau BK, Callister SM, Schell RF.

Clin Dev Immunol. 2012;2012:504215. doi: 10.1155/2012/504215. Epub 2012 Feb 22. Review.


Expansion of the Midwestern focus for human granulocytic anaplasmosis into the region surrounding La Crosse, Wisconsin.

Lovrich SD, Jobe DA, Kowalski TJ, Policepatil SM, Callister SM.

J Clin Microbiol. 2011 Nov;49(11):3855-9. doi: 10.1128/JCM.05025-11. Epub 2011 Sep 14.


Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice.

Kuo J, Nardelli DT, Warner TF, Callister SM, Schell RF.

Clin Vaccine Immunol. 2011 Jul;18(7):1125-32. doi: 10.1128/CVI.00052-11. Epub 2011 May 25.


Rapid decline of OspC borreliacidal antibodies following treatment of patients with early Lyme disease.

Jobe DA, Kowalski TJ, Bloemke M, Lovrich SD, Callister SM.

Clin Vaccine Immunol. 2011 Jun;18(6):1034-7. doi: 10.1128/CVI.00063-11. Epub 2011 Apr 20.


Significant differences between the Borrelia-infection and Borrelia-vaccination and -infection models of Lyme arthritis in C3H/HeN mice.

Nardelli DT, Luedtke JO, Munson EL, Warner TF, Callister SM, Schell RF.

FEMS Immunol Med Microbiol. 2010 Oct;60(1):78-89. doi: 10.1111/j.1574-695X.2010.00721.x.


Use of optical mapping to sort uropathogenic Escherichia coli strains into distinct subgroups.

Schwan WR, Briska A, Stahl B, Wagner TK, Zentz E, Henkhaus J, Lovrich SD, Agger WA, Callister SM, DuChateau B, Dykes CW.

Microbiology. 2010 Jul;156(Pt 7):2124-35. doi: 10.1099/mic.0.033977-0. Epub 2010 Apr 8.


One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin.

LaFleur RL, Callister SM, Dant JC, Jobe DA, Lovrich SD, Warner TF, Wasmoen TL, Schell RF.

Clin Vaccine Immunol. 2010 May;17(5):870-4. doi: 10.1128/CVI.00524-09. Epub 2010 Mar 17.


Lyme borreliosis in dogs and humans in the USA.

Little SE, Heise SR, Blagburn BL, Callister SM, Mead PS.

Trends Parasitol. 2010 Apr;26(4):213-8. doi: 10.1016/ Epub 2010 Mar 6. Review.


Human Lyme disease vaccines: past and future concerns.

Nardelli DT, Munson EL, Callister SM, Schell RF.

Future Microbiol. 2009 May;4(4):457-69. doi: 10.2217/fmb.09.17. Review.


Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.

LaFleur RL, Dant JC, Wasmoen TL, Callister SM, Jobe DA, Lovrich SD, Warner TF, Abdelmagid O, Schell RF.

Clin Vaccine Immunol. 2009 Feb;16(2):253-9. doi: 10.1128/CVI.00373-08. Epub 2008 Dec 3.


Mycobacterium tuberculosis susceptibility testing by flow cytometry.

Schell RF, Nardelli DT, DeCoster DJ, Kirk SM, Callister SM.

Curr Protoc Cytom. 2004 Feb;Chapter 11:Unit 11.7. doi: 10.1002/0471142956.cy1107s27.


Detection of borreliacidal antibodies by flow cytometry.

Callister SM, Jobe DA, Schell RF.

Curr Protoc Cytom. 2004 Nov;Chapter 11:Unit 11.5. doi: 10.1002/0471142956.cy1105s26.


Interleukin-23 is required for development of arthritis in mice vaccinated and challenged with Borrelia species.

Kotloski NJ, Nardelli DT, Peterson SH, Torrealba JR, Warner TF, Callister SM, Schell RF.

Clin Vaccine Immunol. 2008 Aug;15(8):1199-207. doi: 10.1128/CVI.00129-08. Epub 2008 Jun 25.


Role of IL-17, transforming growth factor-beta, and IL-6 in the development of arthritis and production of anti-outer surface protein A borreliacidal antibodies in Borrelia-vaccinated and -challenged mice.

Nardelli DT, Kevin Luk KH, Kotloski NJ, Warner TF, Torrealba JR, Callister SM, Schell RF.

FEMS Immunol Med Microbiol. 2008 Jul;53(2):265-74. doi: 10.1111/j.1574-695X.2008.00431.x. Epub 2008 Jun 3.


Significantly improved accuracy of diagnosis of early Lyme disease by peptide enzyme-linked immunosorbent assay based on the borreliacidal antibody epitope of Borrelia burgdorferi OspC.

Jobe DA, Lovrich SD, Asp KE, Mathiason MA, Albrecht SE, Schell RF, Callister SM.

Clin Vaccine Immunol. 2008 Jun;15(6):981-5. doi: 10.1128/CVI.00079-08. Epub 2008 Apr 16.


Circulating endothelial cells in patients with chronic lymphocytic leukemia.

Go RS, Jobe DA, Asp KE, Callister SM, Mathiason MA, Meyer LA, Bottner WA, Cole CE, Farnen JP, Frisby KA.

Ann Hematol. 2008 May;87(5):369-73. doi: 10.1007/s00277-007-0435-y. Epub 2008 Jan 12.


Lyme arthritis: current concepts and a change in paradigm.

Nardelli DT, Callister SM, Schell RF.

Clin Vaccine Immunol. 2008 Jan;15(1):21-34. Epub 2007 Nov 14. Review. No abstract available.


Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity.

Peterson SH, Nardelli DT, Warner TF, Callister SM, Torrealba JR, Schell RF.

Clin Vaccine Immunol. 2007 May;14(5):510-7. Epub 2007 Mar 14.


Borreliacidal OspC antibody response of canines with Lyme disease differs significantly from that of humans with Lyme disease.

Lovrich SD, La Fleur RL, Jobe DA, Johnson JC, Asp KE, Schell RF, Callister SM.

Clin Vaccine Immunol. 2007 May;14(5):635-7. Epub 2007 Mar 7.


Rapid pyrazinamide susceptibility testing of Mycobacterium tuberculosis by flow cytometry.

Fredricks BA, DeCoster DJ, Kim Y, Sparks N, Callister SM, Schell RF.

J Microbiol Methods. 2006 Nov;67(2):266-72. Epub 2006 May 15.


Anti-interleukin-15 prevents arthritis in Borrelia-vaccinated and -infected mice.

Amlong CA, Nardelli DT, Peterson SH, Warner TF, Callister SM, Schell RF.

Clin Vaccine Immunol. 2006 Feb;13(2):289-96.


Interleukin-6 promotes anti-OspA borreliacidal antibody production in vitro.

Munson EL, Nardelli DT, Luk KH, Remington MC, Callister SM, Schell RF.

Clin Vaccine Immunol. 2006 Jan;13(1):19-25.


CD4(+) CD25(+) T cells prevent arthritis associated with Borrelia vaccination and infection.

Nardelli DT, Cloute JP, Luk KH, Torrealba J, Warner TF, Callister SM, Schell RF.

Clin Diagn Lab Immunol. 2005 Jun;12(6):786-92.


Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.

Lovrich SD, Jobe DA, Schell RF, Callister SM.

Clin Diagn Lab Immunol. 2005 Jun;12(6):746-51. Erratum in: Clin Diagn Lab Immunol. 2005 Sep;12(9):1139.


Human cyclic thrombocytopenia and Anaplasma spp. infection.

Go RS, Lovrich SD, Callister SM, Meyer LA, Bottner WA, Farnen JP.

Eur J Haematol. 2005 Feb;74(2):182-3. No abstract available.


High prevalence of genital mycoplasmas among sexually active young adults with urethritis or cervicitis symptoms in La Crosse, Wisconsin.

Schlicht MJ, Lovrich SD, Sartin JS, Karpinsky P, Callister SM, Agger WA.

J Clin Microbiol. 2004 Oct;42(10):4636-40.


Neutralization of gamma interferon augments borreliacidal antibody production and severe destructive Lyme arthritis in C3H/HeJ mice.

Munson EL, DeCoster DJ, Nardelli DT, England DM, Callister SM, Schell RF.

Clin Diagn Lab Immunol. 2004 Jan;11(1):35-41.


C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease.

Jobe DA, Lovrich SD, Schell RF, Callister SM.

Clin Diagn Lab Immunol. 2003 Jul;10(4):573-8.


Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi.

Burchill MA, Nardelli DT, England DM, DeCoster DJ, Christopherson JA, Callister SM, Schell RF.

Infect Immun. 2003 Jun;71(6):3437-42.


Destructive arthritis in vaccinated interferon gamma-deficient mice challenged with Borrelia burgdorferi: modulation by tumor necrosis factor alpha.

Christopherson JA, Munson EL, England DM, Croke CL, Remington MC, Molitor ML, DeCoster DJ, Callister SM, Schell RF.

Clin Diagn Lab Immunol. 2003 Jan;10(1):44-52.


Gamma interferon inhibits production of Anti-OspA borreliacidal antibody in vitro.

Munson EL, Du Chateau BK, Jensen JR, Callister SM, DeCoster DJ, Schell RF.

Clin Diagn Lab Immunol. 2002 Sep;9(5):1095-101.


Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Callister SM, Jobe DA, Agger WA, Schell RF, Kowalski TJ, Lovrich SD, Marks JA.

Clin Diagn Lab Immunol. 2002 Jul;9(4):908-12.


Reassessment of a midwestern Lyme disease focus for Borrelia burgdorferi and the human granulocytic ehrlichiosis agent.

Jackson CA, Lovrich SD, Agger WA, Callister SM.

J Clin Microbiol. 2002 Jun;40(6):2070-3.


Interleukin-6 enhances production of anti-OspC immunoglobulin G2b borreliacidal antibody.

Remington MC, Munson EL, Callister SM, Molitor ML, Christopherson JA, DeCoster DJ, Lovrich SD, Schell RF.

Infect Immun. 2001 Jul;69(7):4268-75.


Flow cytometric testing of susceptibilities of Mycobacterium avium to amikacin, ciprofloxacin, clarithromycin and rifabutin in 24 hours.

Vena RM, Munson EL, DeCoster DJ, Croke CL, Fett DB, Callister SM, Schell RF.

Clin Microbiol Infect. 2000 Jul;6(7):368-75.


Detection of borreliacidal antibodies in dogs after challenge with Borrelia burgdorferi-infected ixodes scapularis ticks.

Callister SM, Jobe DA, Schell RF, Lovrich SD, Onheiber KL, Korshus JB.

J Clin Microbiol. 2000 Oct;38(10):3670-4.

Supplemental Content

Loading ...
Support Center